Machine Learning-Assisted Iterative Screening for Efficient Detection of Drug Discovery Starting Points
High-throughput screening (HTS) remains central to small molecule lead discovery, but increasing assay complexity challenges the screening of large compound libraries. While retrospective studies have assessed active-learning-guided screening, extensive prospective validations are rare. Here, we report the first prospective evaluation of machine learning (ML)-assisted iterative HTS in a large-scale drug discovery project. Using a mass spectrometry-based assay for salt-inducible kinase 2, we screened just 5.9% of a two million-compound library in three batches and recovered 43.3% of all primary actives identified in a parallel full HTS─including all but one compound series selected by medicinal chemists. This demonstrates that ML-guided iterative screening can significantly reduce the experimental cost while maintaining hit discovery quality. Retrospective benchmarks further showed that the ML approach outperforms similarity-based methods in hit recovery and chemical space coverage. In summary, this study highlights the potential of ML-driven iterative HTS to improve efficiency also in large-scale drug discovery projects.
Authors
- Michael Reutlinger (ORCID: https://orcid.org/0000-0001-9393-108X)
- Bigna Wörsdörfer
- Wolfgang Haap (ORCID: https://orcid.org/0000-0001-6845-2124)
- Alex T. Müller (ORCID: https://orcid.org/0000-0001-8063-9952)
- Paul Westwood
- Dominik Heer (ORCID: https://orcid.org/0009-0003-2089-4339)
- Christian Krämer (ORCID: https://orcid.org/0000-0001-8663-5266)
- Markus Hierl
- Doris Roth
- Philippe Hartz
Institutions
- Roche (Switzerland) (CH)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c00943
- Citations
- 3
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 4.51